Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
April 2, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
a man holding a ball in his right hand

Photo by julien Tromeur on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • 94% of physicians have already adopted AI tools or are interested in doing so, with more than half now using AI in their practice — up from 47% in early 2025 to 63% by late 2025 and early 2026, per a Doximity survey of over 3,000 doctors
  • More than 70% of physicians cited accuracy and reliability as a top barrier to broader AI adoption, and nearly half pointed to legal and regulatory uncertainty
  • Three-quarters of physicians who had already adopted AI reported reduced administrative burden and better job satisfaction; nearly half said AI improved their capacity to take on new patients
  • Only 8% of physicians said their organization’s AI decision-making process is clear and well-understood — while about half said it is “still evolving” — highlighting a significant governance gap

What Happened?

A new survey by Doximity, the medical professional network and technology company, finds that AI adoption among physicians is accelerating rapidly — but concerns about accuracy and unclear organizational governance are slowing full integration. Of more than 3,000 physicians surveyed across two periods, 94% said they had already adopted AI tools or are interested in doing so, with just 5% saying they weren’t interested. Adoption has surged: 47% reported using AI during the first survey period in early 2025; by the second period from November through January, that figure had risen to 63%. The most common use cases were literature search and AI-powered scribing tools that record patient conversations and draft clinical documentation. Despite the rapid adoption, more than 70% cited accuracy and reliability as a top barrier, and nearly half flagged legal and regulatory uncertainty as a concern.

Why It Matters?

The Doximity survey captures a pivotal inflection point in healthcare AI: the technology has crossed from “early adopter” territory to mainstream clinical interest in under three years, but the infrastructure — governance, regulation, and trust — hasn’t kept pace. The gap is most visible in organizational readiness: only 8% of physicians said their organization’s AI policies and guidelines are clear, while about half said the process is “still evolving.” That ambiguity creates liability exposure for health systems and confusion for individual clinicians trying to deploy AI responsibly. For healthcare investors, the survey underscores both the size of the opportunity and the friction that remains. The AI tools generating the most physician enthusiasm — scribing, literature search, administrative automation — are also among the lower-risk applications, suggesting adoption will continue to build from the bottom up before moving into higher-stakes clinical decision support.

What’s Next?

The governance gap is the most actionable finding for health systems: with 92% of physicians either using or interested in AI, the question is no longer whether to deploy these tools but how to deploy them safely and with clear institutional policies. Organizations that move quickly to establish clear guidelines, training, and accountability frameworks will be better positioned to capture the productivity and retention benefits AI can deliver — and to avoid the legal and regulatory exposure that currently concerns nearly half of physicians. For AI vendors, the survey signals strong underlying demand but also the need to invest in accuracy validation and explainability, given that reliability concerns are the top barrier. Regulatory clarity from the FDA and CMS on AI-powered clinical tools will be a critical catalyst for the next phase of adoption.

Source: Healthcare Dive

Previous Post

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

Next Post

Trump Threatens to Escalate Iran War — But Says End Is ‘Very Close’

Recommended For You

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
3 days ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
5 days ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
2 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
2 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
2 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
3 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 month ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
1 month ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more
Next Post
House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

Trump Threatens to Escalate Iran War — But Says End Is 'Very Close'

Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

Supreme Court Signals It Will Strike Down Trump's Birthright Citizenship Order

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Alphabet $GOOGL Q2 2024 Results

Google Ruling Shows Antitrust Tools Struggle to Keep Up With Tech Markets

September 4, 2025
Walmart Expands Logistics Services Beyond Its Marketplace: What This Means for Investors

China Summons Walmart Over Supplier Price Cuts Amid Escalating Trade Tensions

March 12, 2025
low angle view of building

U.S. Apartment Rents Poised for Nationwide Increase as Market Shifts to Landlord-Friendly Terrain

February 14, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018